Adjunctive treatment in juvenile nasopharyngeal angiofibroma
Scholfield, Daniel W; Brundler, Marie-Anne; McDermott, Ann-Louise; Mussai, Francis; Kearns, Pamela

DOI: 10.1097/MPH.0000000000000524
License: None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Final Version of Record published as detailed above.
Checked June 2016

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 23. Aug. 2019
Adjunctive Treatment In Juvenile Nasopharyngeal Angiofibroma: How Should We Approach Recurrence?

Daniel W Scholfield BSc (Hons) MBChB, Marie-Anne Brundler MD FRCPath, Ann-Louise McDermott FDS RCS FRCS, Francis Mussai MA (Oxon) BCh DPhil MRCPCH, Pamela Kearns MBChB BSc (Hons) PhD FRCPCH.

1Paediatric Oncology Department, Birmingham Children’s Hospital
2Department of Pathology, Birmingham Children’s Hospital, Birmingham UK
3ENT Department, Birmingham Children’s Hospital, Birmingham UK
4School of Cancer Sciences, University of Birmingham, UK

Disclosures:
The authors have no conflicts of interest or funding to disclose.

Correspondence:
Daniel Scholfield
Whipps Cross Hospital
London, UK
E11 1NR
Email: danwscholfield@doctors.org.uk
Telephone: +44(0) 7817 262259

Key words:
Juvenile Nasopharyngeal Angiofibroma
Radiotherapy
Flutamide
Dexamethasone
Abstract

A recent case of advanced, recurrent Juvenile Nasopharyngeal Angiofibroma (JNA) at our institution has highlighted the limited evidence regarding adjunctive treatment. We present the case of a ten year old boy who is the first to undergo multiple staged surgical resections alongside vincristine treatment. We performed a review of the literature analyzing the roles of radiation therapy, cytotoxic drugs and novel targeted agents in JNA relapse. Small cohort studies suggest radiotherapy and flutamide are the most rational treatment options for residual and recurrent JNA. Our review highlights the need for further research into the management of primary and recurrent JNA.

Introduction

Juvenile nasopharyngeal angiofibroma (JNA) is a benign, highly vascular and locally invasive lesion that develops almost exclusively in the nasopharynx of peripubertal boys. JNA represents 0.5% of all head and neck tumors, with an incidence of approximately 1:150,000. Large cohort studies report median ages of 15 years (range 10-24 years) and 18.5 years (range 18-35 years) (1).

Histologically JNA is pseudocapsulated, characterized by an irregular vascular component embedded in a fibrous stroma, densely populated by collagen and fibroblasts. Mitotic figures are rare and the vessels are organized in clusters, without elastic fibers in their walls or a muscular lining in smaller vessels (2). Electron microscopy and immunohistological studies demonstrating morphological irregularities such as focal lack of pericytes, discontinuous vascular basal laminae and irregularity of smooth muscle layers, suggest that JNA is not a tumor, but a vascular malformation (3). JNA originates from the first branchial arch artery and usually regresses between embryological day 22 and 24 to form a venous plexus in the sphenopalatine foramen, the typical site of JNA origin. Incomplete regression of the vascular plexus leaves it vulnerable to growth stimulation at the time of
adolescence to form JNA (3). Predominance in adolescent males suggests a hormonal influence on
growth, supported by the presence of androgen receptors on JNA cell membranes (4). The male to
female ratio of patients in our review is 94:0.

JNA is locally destructive, often extending intracranially into the paranasal sinuses and along the
skull base (5). Patients present with nasal obstruction, facial numbness, headaches and visual
changes (6). Nasal endoscopy typically reveals a large hypervascularized, lobulated mass extending
into the nasopharynx and diagnosis is confirmed with computed tomography (CT), which usually
reveals widening of the sphenopalatine foramen and extension into surrounding areas (5). Contrast
enhanced magnetic resonance imaging (MRI) shows further characteristic features - “flow voids”
caused by the highly vascular nature of JNA. MRI is superior to CT for diagnosis and surgical planning
due to greater sensitivity in distinguishing JNA from retained mucous or inflammation, eliminating
other benign or malignant tumors and assessing intracranial extent (1).

Surgery remains the mainstay of treatment, preceded by intravascular embolization to reduce intra-
operative bleeding (5). Adjunctive radiotherapy and chemotherapy are uncommon, but may be the
only option in inoperable recurrence. A recent case at our institution has highlighted the
exceptionally limited evidence regarding adjunctive treatment and questions how best to approach
recurrence.

Case

A ten year old boy presented to our institution with a two month history of deteriorating vision and
proptosis of his right eye. He complained of nasal obstruction and sleep disordered breathing for
more than a year and examination revealed a large right-sided nasal mass, paraesthesia of his right cheek, nose and teeth, a right middle ear effusion and displacement of the right tonsil. CT and MRI exhibited features consistent with Stage 4 JNA (Fisch classification, see Table I) (Figure 1). The patient underwent pre-operative embolization of the right internal maxillary artery and other significant bilateral tumor feeding vessels with Onyx (Ethylene vinyl alcohol copolymer), followed by the first stage of endoscopic transnasal resection. An extended endoscopic approach utilizing a Denker’s maxilotomy was performed, although extensive blood loss limited the procedure.

Histology of the resected specimen showed a spindle cell lesion containing numerous angulated and circular vascular spaces (Figure 2a). Cells showed relatively plump nuclei with small indistinct nucleoli and the background stroma was mainly composed of dense fibrous tissue. Immunohistochemistry revealed the cells to be strongly positive for β-catenin (Figure 2b) and vimentin (Figure 2c). CD31 and CD34 highlighted angulated and larger ectatic vessels.

Post-operative MRI scan confirmed a substantial residual tumor encasing the right internal carotid artery (ICA), with extension between the pterygoid muscles down to the angle of the mandible. The case was discussed by pediatric oncology, radiation oncology and otolaryngology teams at a multi-disciplinary meeting, with particular focus on the problem of excessive blood loss despite embolization.

No standard therapeutic approach exists for recurrent and unresectable JNA. Based on a small case series the patient was treated with 1.5mg/m2 of vincristine weekly for four weeks, with the aim of assessing chemosensitivity prior to surgery.
Restaging MRI six weeks post-operatively showed the tumor had failed to respond and had increased in size to 75 x 75 x 45 mm (anteroposterior x craniocaudal x transverse long axis), categorized by Response Evaluation Criteria in Solid Tumors (RECIST) as progressive disease. Further endoscopic resection with embolization took place, again limited by blood loss and the risk of deranged clotting from repeated transfusions. Extensive resection via an expanded endonasal approach (EEA) was subsequently achieved. Four months post-surgery, MRI scans revealed a residuum adjacent to the internal carotid artery. The child has since made an excellent recovery and is currently under surveillance. MRI scans show no disease progression 28 months post-surgery via EEA.

This case raises the question of management options in the event of further growth. A review of possible therapeutic options is outlined below and summary provided in Table II.

Discussion and Review of Adjunctive Treatment

Biopsy is contra-indicated in JNA due to its highly vascularized nature. Accurate diagnosis and differentiation from parameningeal tumors relies on MRI imaging, whilst CT provides bony landmarks for surgery. Characteristics signs on MRI include signal voids that represent major intra-lesional vessels, “finger-like” projections of JNA extension into soft tissue and submucosal invasion of the basisphenoid (1). Combining these characteristics leads to the diagnosis of JNA. There have been no reports in the literature of these characteristic signs being present in other lesions.
JNA is principally a surgical lesion that should initially be discussed with the otolaryngology team after recurrence. Transnasal endoscopic resections are most effective in combination with preoperative embolization. The surgical approach involves extensive exposure of the tumor, utilizing resection of the posterior third of the nasal septum and the posterior wall of the maxillary sinus. Accurate subperiosteal dissection and extensive drilling of any bone adhered to by JNA completes the procedure (2). Endoscopic excision of smaller tumors is the gold standard for surgical resection due to significantly reduced blood loss. The EEA approach utilizes the same principles in tackling larger lesions that extend intracranially and into the skull base, the key advantage being that it provides access to more deeply seated lesions (1).

Control of bleeding is the most significant intraoperative challenge, whilst skull base infiltration or encasement of the ICA provide further surgical hazards that may result in inoperability. In contrast to malignancies of the nasopharynx, such as rhabdomyosarcoma, a “piecemeal” resection is acceptable and often preferable when approaching difficult anatomical locations (1). Endoscopic surgery is contraindicated in residual tumors involving critical areas and it is in these cases where adjuvant therapy needs to be discussed.

Radiation therapy (RT) for JNA is a contentious topic due to the potential for malignant transformation to fibrosarcoma, although only two cases are reported in the literature, occurring 18 and 20 years after radiation (7, 8). Other long term sequelae include growth impairment, encephalopathy and secondary malignancies (1, 9). Nevertheless, adjuvant radiotherapy is recommended by some authors after incomplete resection (5). McAfee et al used RT to treat 22 adolescent males with high stage JNA, with a total dose range of 30 to 36 Gy (9). Ten were for primary treatment and 12 for recurrence, resulting in local control in 90% of patients, with a median
follow up of 12.7 years. However, late complications occurred in 32% of patients, including transient ischemic vascular stroke and basal cell carcinoma. Long term complications also occurred in a study of 27 patients, where RT was used as primary treatment (30-55 Gy) for advanced JNA (10). The recurrence rate was 15% at 2 to 5 years and 15% suffered complications. Nevertheless, the authors concluded that the risk of surgical intervention in advanced JNA is greater than the risk of fatal RT complications. The concern for damage to surrounding structures by conventional RT may be overcome by intensity-modulated radiation therapy (IMRT), offering superior target coverage and lower risk to surrounding tissue (6). Chakraborty et al treated 8 patients with conformal RT, including 7 with IMRT, with a median age of 14 years (11). At last follow up 87.5% were free of disease (median: 17 months), whilst one patient died a month after radiotherapy due to massive epistaxis.

There are few reports on the use of cytotoxic drugs for treatment of JNA. Goepfert et al described tumor remission in five patients with recurrent disease using combinations of doxorubicin, vincristine, dactinomycin and cyclophosphamide, none of which had further recurrence (12). Schick et al reported a patient with advanced and unresectable disease who underwent palliative treatment with adriamycin and decarbazine, which led to a partial response (RECIST) (13). Limited evidence and lack of randomized control trials result in chemotherapy approaches that are not uniform and remain experimental in nature.

The growth of JNA is highly influenced by hormonal levels, due to the presence of testosterone and dihydrotestosterone receptors. Hwang et al provided immunocytochemical evidence for the presence of androgen receptors (AR) on 75% of JNAs using antibodies to AR (4). The non-steroidal androgen antagonist, flutamide, blocks androgen receptors without the side effects of estrogen analogues. Gates et al conducted a pilot study of five male patients with Fisch stage I – III lesions.
(Table I), treated pre-operatively with 500mg/day of flutamide for six weeks (14). CT showed tumor volume reduction in four patients and increase in one, resulting in a mean volume reduction of 29%. Flutamide was well tolerated and serum testosterone levels were normal 2 years post operatively, although it is not clear whether the patients remained in remission. Labra et al investigated the effect of flutamide on seven patients with advanced intracranial disease and a mean age of 15.6 years (Fisch stage IV; Table I) (15). 600mg/day of flutamide was administered for three weeks pre-operatively resulting in a non-statistically significant mean volume reduction of 7.2%. The larger tumor size (mean 202.45 cm³), stage or shorter course may have contributed to the ineffectiveness of flutamide in this study. Thakar et al performed a phase II evaluation of activity and safety of flutamide (16). Their study included 20 male patients with Fisch stage II – IV JNA (Table I) with a mean age of 15.7 years. A six week course of 10mg/kg/day was chosen based on Gates et al’s regime and tumor volume was assessed by MRI (14). Pre-pubertal patients had a mean reduction of -2.3% including two patients that had significant tumor progression. Conversely, post-pubertal patients had a mean volume reduction of 16.5% (p=0.04). However, volume reduction was only partially attributed to serum testosterone levels (R² = 0.28) and the study does not report data on event free and overall survival. Three patients with tumor recurrence showed a reduction in JNA volume of 7%, 12% and 18%, suggesting flutamide may be a treatment option in post-excision residual or recurrent intracranial and extracranial JNA. These pilot studies suggest that a six week course of flutamide may have some activity in treating recurrent JNA, particularly in post-pubertal boys. Further investigation into adjuvant or salvage flutamide treatment is warranted, as the current evidence on flutamide efficacy is not entirely convincing.

The vascular endothelial growth factor (VEGF) pathway plays a key role in solid tumor angiogenesis. Saylam et al found that 24 of 27 JNA samples were VEGF positive, including all cases of recurrence tested (17). Bevacizumab is a humanized monoclonal antibody that inhibits VEGF-A and could be a
potential therapeutic option, although there are no reports of VEGF inhibitors being investigated as
treatment for JNA to date.

Schick et al found that estrogen receptor alpha mRNA is more significant in JNA cell lines than in the
stroma of nasal mucosa (18). The estrogen receptor antagonist tamoxifen was also demonstrated to
inhibit proliferation of cultured JNA mesenchymal cells. However, side-effects of tamoxifen limit its
clinical use for this indication. Selective estrogen antagonists are being developed, but other specific
molecular targets currently remain a more realistic option for experimental treatment of JNA.

Wendler et al demonstrated the greater anti-proliferative effects of glucocorticoids on 30 JNA tissue
samples compared to 20 nasal mucosa tissues in vitro (19). They also showed up-regulation of
glucocorticoid receptors in JNA tissue compared to nasal mucosa. Glucocorticoids are reported to
downregulate VEGF, reducing microvessel density and tumor volume (19). This is of particular
interest in JNA because of previously described overexpression of VEGF (17), making glucocorticoids
an intriguing but untested option for management of unresectable or recurrent JNA.

The mTOR (mammalian target of rapamycin) inhibitor sirolimus (rapamycin) and its analogues may
offer effective targeted treatment for JNA, due to its highly vascular nature. They are potent
inhibitors of serine/threonine kinase, which control cellular growth processes. Notably they appear
to have antiangiogenic activity and have led to partial response in a case series of six patients with
kaposiform hemangioendotheliomas (20).
Beta blockers are used in infantile hemangiomas to reduce the expression of VEGF and it has been theorized that propranolol induces apoptosis due to involvement of β1-adrenoreceptors in angiogenesis (20). Both mTOR inhibitors and beta blockers are options for further research into JNA treatment.

**Conclusion**

Managing recurrent and unresectable JNA remains a challenge. The absence of randomized control trials for anti-neoplastic drugs and RT means the role of adjuvant therapy is not well established. The greatest body of evidence surrounds radiation therapy or a six week course of flutamide, but both are based on small cohorts. Dexamethasone is a possible therapeutic option due to its potential impact on multiple pathways, but this is yet to be proven in a clinical setting. There is a biological rationale for anti-angiogenic agents and trials on anti-endoglin monoclonal antibodies are on-going, but VEGF-inhibitors such as bevacizumab have yet to be investigated. Should recurrence occur in the patient described in this case, the evidence-base for effective treatment is limited, particularly as being pre-pubertal reduces the potential benefit of flutamide. Radiotherapy is likely to remain the next most rational course of therapy. It has been demonstrated to effectively reduce tumor volume and is the best option for long term survival despite the potential side effects, until more targeted therapeutic options are fully evaluated. JNA is a biologically rich tumor and there is a clear need for clinical research to evaluate adjuvant treatments to improve the outcome for recurrent and inoperable JNA.
Acknowledgements

The authors would like to thank Carl H. Snyderman C, Elizabeth C. Tyler-Kabara and Paul A. Gardner at the University Of Pittsburgh Medical Centre (UPMC) for their invaluable advice and surgical expertise in managing the case described.
References


Figures

Figure 1: Coronal MRI image showing an extensive JNA extending laterally into the pterygopalatine and masseter spaces and inferiorly into the infratemporal fossa. It extends into the right cavernous sinus and involves the right Meckel’s cave.

Figure 2: Pathology micrographs of the JNA featured in the case: 2a) Hematoxylin and eosin stain; 2b) β-Catenin stain; 2c) Vimentin stain.
Table I: Fisch Classification of Juvenile Nasopharyngeal Angiofibroma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Limited to the nasopharynx and nasal cavity without bone destruction.</td>
</tr>
<tr>
<td>II</td>
<td>Invading the pterygomaxillary fossa and the maxillary, ethmoid and sphenoid sinus with bone destruction.</td>
</tr>
<tr>
<td>III</td>
<td>Invading the infratemporal fossa, orbit and parasellar region remaining lateral to the cavernous sinus.</td>
</tr>
<tr>
<td>IV</td>
<td>Massive invasion of cavernous sinus, the optic chiasmal region or pituitary fossa.</td>
</tr>
</tbody>
</table>
## Table II: Summary of adjunctive treatment of JNA

<table>
<thead>
<tr>
<th>Study [reference]</th>
<th>Patient number</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Radiation Therapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McAfee et al (2006) [9]</td>
<td>22</td>
<td>30 – 36 Gy</td>
<td>Local control in 90% of patients, late complications in 32%</td>
</tr>
<tr>
<td>Lee et al (2002) [10]</td>
<td>27</td>
<td>30-55 Gy</td>
<td>Recurrence in 15% of patients, complications in 15%</td>
</tr>
<tr>
<td><strong>Cytotoxic Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goepfert et al (1985) [12]</td>
<td>5</td>
<td>Doxorubicin, vincristine, dactinomycin and cyclophosphamide</td>
<td>0% recurrence</td>
</tr>
<tr>
<td><strong>Flutamide</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gates et al (1992) [14]</td>
<td>5</td>
<td>500mg/day for 6 weeks pre-operatively</td>
<td>Mean volume reduction: 29%</td>
</tr>
<tr>
<td>Thakar et al (2011) [16]</td>
<td>20</td>
<td>10mg/kg/day for 6 weeks</td>
<td>Mean volume reduction: -2.3% in pre-pubertal, 16.5% in post-pubertal</td>
</tr>
<tr>
<td><strong>Targeted therapies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saylam et al (2006) [17]</td>
<td>N/A – in vitro</td>
<td>89% of JNA samples VEGF positive</td>
<td></td>
</tr>
</tbody>
</table>
Adjunctive Treatment In Juvenile Nasopharyngeal Angiofibroma: How Should We Approach Recurrence?

Daniel W Scholfield BSc (Hons) MBChB\textsuperscript{1}, Marie-Anne Brundler MD FRCPath\textsuperscript{2}, Ann-Louise McDermott FDS RCS FRCS\textsuperscript{3}, Francis Mussai MA (Oxon) BM BCh DPhil MRCPCH\textsuperscript{1,4}, Pamela Kearns MBChB BSc (Hons) PhD FRCPCH\textsuperscript{1,4}

\textsuperscript{1}Paediatric Oncology Department, Birmingham Children’s Hospital
\textsuperscript{2}Department of Pathology, Birmingham Children’s Hospital, Birmingham UK
\textsuperscript{3}ENT Department, Birmingham Children’s Hospital, Birmingham UK
\textsuperscript{4}School of Cancer Sciences, University of Birmingham, UK

Disclosures:
The authors have no conflicts of interest or funding to disclose.

Correspondence:
Daniel Scholfield
Whipps Cross Hospital
London, UK
E11 1NR
Email: danwscholfield@doctors.org.uk
Telephone: +44(0) 7817 262259

Key words:
Juvenile Nasopharyngeal Angiofibroma
Radiotherapy
Flutamide
Dexamethasone
Abstract

A recent case of advanced, recurrent Juvenile Nasopharyngeal Angiofibroma (JNA) at our institution has highlighted the limited evidence regarding adjunctive treatment. We present the case of a ten year old boy who is the first to undergo multiple staged surgical resections alongside vincristine treatment. We performed a review of the literature analyzing the roles of radiation therapy, cytotoxic drugs and novel targeted agents in JNA relapse. Small cohort studies suggest radiotherapy and flutamide are the most rational treatment options for residual and recurrent JNA. Our review highlights the need for further research into the management of primary and recurrent JNA.

Introduction

Juvenile nasopharyngeal angiofibroma (JNA) is a benign, highly vascular and locally invasive lesion that develops almost exclusively in the nasopharynx of peripubertal boys. JNA represents 0.5% of all head and neck tumors, with an incidence of approximately 1:150,000. Large cohort studies report median ages of 15 years (range 10-24 years) and 18.5 years (range 18-35 years) (1).

Histologically JNA is pseudocapsulated, characterized by an irregular vascular component embedded in a fibrous stroma, densely populated by collagen and fibroblasts. Mitotic figures are rare and the vessels are organized in clusters, without elastic fibers in their walls or a muscular lining in smaller vessels (2). Electron microscopy and immunohistological studies demonstrating morphological irregularities such as focal lack of pericytes, discontinuous vascular basal laminae and irregularity of smooth muscle layers, suggest that JNA is not a tumor, but a vascular malformation (3). JNA originates from the first branchial arch artery and usually regresses between embryological day 22 and 24 to form a venous plexus in the sphenopalatine foramen, the typical site of JNA origin. Incomplete regression of the vascular plexus leaves it vulnerable to growth stimulation at the time of
adolescence to form JNA (3). Predominance in adolescent males suggests a hormonal influence on
growth, supported by the presence of androgen receptors on JNA cell membranes (4). The male to
female ratio of patients in our review is 94:0.

JNA is locally destructive, often extending intracranially into the paranasal sinuses and along the
skull base (5). Patients present with nasal obstruction, facial numbness, headaches and visual
changes (6). Nasal endoscopy typically reveals a large hypervascularized, lobulated mass extending
into the nasopharynx and diagnosis is confirmed with computed tomography (CT), which usually
reveals widening of the sphenopalatine foramen and extension into surrounding areas (5). Contrast
enhanced magnetic resonance imaging (MRI) shows further characteristic features - “flow voids”
caused by the highly vascular nature of JNA. MRI is superior to CT for diagnosis and surgical planning
due to greater sensitivity in distinguishing JNA from retained mucous or inflammation, eliminating
other benign or malignant tumors and assessing intracranial extent (1).

Surgery remains the mainstay of treatment, preceded by intravascular embolization to reduce intra-
operative bleeding (5). Adjunctive radiotherapy and chemotherapy are uncommon, but may be the
only option in inoperable recurrence. A recent case at our institution has highlighted the
exceptionally limited evidence regarding adjunctive treatment and questions how best to approach
recurrence.

Case

A ten year old boy presented to our institution with a two month history of deteriorating vision and
proptosis of his right eye. He complained of nasal obstruction and sleep disordered breathing for
more than a year and examination revealed a large right-sided nasal mass, paraesthesia of his right cheek, nose and teeth, a right middle ear effusion and displacement of the right tonsil. CT and MRI exhibited features consistent with Stage 4 JNA (Fisch classification, see Table I) (Figure 1). The patient underwent pre-operative embolization of the right internal maxillary artery and other significant bilateral tumor feeding vessels with Onyx (Ethylene vinyl alcohol copolymer), followed by the first stage of endoscopic transnasal resection. An extended endoscopic approach utilizing a Denker’s maxilotomy was performed, although extensive blood loss limited the procedure.

Histology of the resected specimen showed a spindle cell lesion containing numerous angulated and circular vascular spaces (Figure 2a). Cells showed relatively plump nuclei with small indistinct nucleoli and the background stroma was mainly composed of dense fibrous tissue. Immunohistochemistry revealed the cells to be strongly positive for β-catenin (Figure 2b) and vimentin (Figure 2c). CD31 and CD34 highlighted angulated and larger ectatic vessels.

Post-operative MRI scan confirmed a substantial residual tumor encasing the right internal carotid artery (ICA), with extension between the pterygoid muscles down to the angle of the mandible. The case was discussed by pediatric oncology, radiation oncology and otolaryngology teams at a multi-disciplinary meeting, with particular focus on the problem of excessive blood loss despite embolization.

No standard therapeutic approach exists for recurrent and unresectable JNA. Based on a small case series the patient was treated with 1.5mg/m2 of vincristine weekly for four weeks, with the aim of assessing chemosensitivity prior to surgery.
Restaging MRI six weeks post-operatively showed the tumor had failed to respond and had increased in size to 75 x 75 x 45 mm (anteroposterior x craniocaudal x transverse long axis), categorized by Response Evaluation Criteria in Solid Tumors (RECIST) as progressive disease. Further endoscopic resection with embolization took place, again limited by blood loss and the risk of deranged clotting from repeated transfusions. Extensive resection via an expanded endonasal approach (EEA) was subsequently achieved. Four months post-surgery, MRI scans revealed a residuum adjacent to the internal carotid artery. The child has since made an excellent recovery and is currently under surveillance. MRI scans show no disease progression 28 months post-surgery via EEA.

This case raises the question of management options in the event of further growth. A review of possible therapeutic options is outlined below and summary provided in Table II.

**Discussion and Review of Adjunctive Treatment**

Biopsy is contra-indicated in JNA due to its highly vascularized nature. Accurate diagnosis and differentiation from parameningeal tumors relies on MRI imaging, whilst CT provides bony landmarks for surgery. Characteristics signs on MRI include signal voids that represent major intralessional vessels, “finger-like” projections of JNA extension into soft tissue and submucosal invasion of the basisphenoid (1). Combining these characteristics leads to the diagnosis of JNA. There have been no reports in the literature of these characteristic signs being present in other lesions.
JNA is principally a surgical lesion that should initially be discussed with the otolaryngology team after recurrence. Transnasal endoscopic resections are most effective in combination with preoperative embolization. The surgical approach involves extensive exposure of the tumor, utilizing resection of the posterior third of the nasal septum and the posterior wall of the maxillary sinus. Accurate subperiosteal dissection and extensive drilling of any bone adhered to by JNA completes the procedure (2). Endoscopic excision of smaller tumors is the gold standard for surgical resection due to significantly reduced blood loss. The EEA approach utilizes the same principles in tackling larger lesions that extend intracranially and into the skull base, the key advantage being that it provides access to more deeply seated lesions (1).

Control of bleeding is the most significant intraoperative challenge, whilst skull base infiltration or encasement of the ICA provide further surgical hazards that may result in inoperability. In contrast to malignancies of the nasopharynx, such as rhabdomyosarcoma, a “piecemeal” resection is acceptable and often preferable when approaching difficult anatomical locations (1). Endoscopic surgery is contraindicated in residual tumors involving critical areas and it is in these cases where adjuvant therapy needs to be discussed.

Radiation therapy (RT) for JNA is a contentious topic due to the potential for malignant transformation to fibrosarcoma, although only two cases are reported in the literature, occurring 18 and 20 years after radiation (7, 8). Other long term sequelae include growth impairment, encephalopathy and secondary malignancies (1, 9). Nevertheless, adjuvant radiotherapy is recommended by some authors after incomplete resection (5). McAfee et al used RT to treat 22 adolescent males with high stage JNA, with a total dose range of 30 to 36 Gy (9). Ten were for primary treatment and 12 for recurrence, resulting in local control in 90% of patients, with a median
follow up of 12.7 years. However, late complications occurred in 32% of patients, including transient ischemic vascular stroke and basal cell carcinoma. Long term complications also occurred in a study of 27 patients, where RT was used as primary treatment (30-55 Gy) for advanced JNA (10). The recurrence rate was 15% at 2 to 5 years and 15% suffered complications. Nevertheless, the authors concluded that the risk of surgical intervention in advanced JNA is greater than the risk of fatal RT complications. The concern for damage to surrounding structures by conventional RT may be overcome by intensity-modulated radiation therapy (IMRT), offering superior target coverage and lower risk to surrounding tissue (6). Chakraborty et al treated 8 patients with conformal RT, including 7 with IMRT, with a median age of 14 years (11). At last follow up 87.5% were free of disease (median: 17 months), whilst one patient died a month after radiotherapy due to massive epistaxis.

There are few reports on the use of cytotoxic drugs for treatment of JNA. Goepfert et al described tumor remission in five patients with recurrent disease using combinations of doxorubicin, vincristine, dactinomycin and cyclophosphamide, none of which had further recurrence (12). Schick et al reported a patient with advanced and unresectable disease who underwent palliative treatment with Adriamycin and decarbazine, which led to a partial response (RECIST) (13). Limited evidence and lack of randomized control trials result in chemotherapy approaches that are not uniform and remain experimental in nature.

The growth of JNA is highly influenced by hormonal levels, due to the presence of testosterone and dihydrotestosterone receptors. Hwang et al provided immunocytochemical evidence for the presence of androgen receptors (AR) on 75% of JNAs using antibodies to AR (4). The non-steroidal androgen antagonist, flutamide, blocks androgen receptors without the side effects of estrogen analogues. Gates et al conducted a pilot study of five male patients with Fisch stage I – III lesions.
(Table I), treated pre-operatively with 500mg/day of flutamide for six weeks (14). CT showed tumor volume reduction in four patients and increase in one, resulting in a mean volume reduction of 29%. Flutamide was well tolerated and serum testosterone levels were normal 2 years post operatively, although it is not clear whether the patients remained in remission. Labra et al investigated the effect of flutamide on seven patients with advanced intracranial disease and a mean age of 15.6 years (Fisch stage IV; Table I) (15). 600mg/day of flutamide was administered for three weeks pre-operatively resulting in a non-statistically significant mean volume reduction of 7.2%. The larger tumor size (mean 202.45 cm³), stage or shorter course may have contributed to the ineffectiveness of flutamide in this study. Thakar et al performed a phase II evaluation of activity and safety of flutamide (16). Their study included 20 male patients with Fisch stage II – IV JNA (Table I) with a mean age of 15.7 years. A six week course of 10mg/kg/day was chosen based on Gates et al’s regime and tumor volume was assessed by MRI (14). Pre-pubertal patients had a mean reduction of -2.3% including two patients that had significant tumor progression. Conversely, post-pubertal patients had a mean volume reduction of 16.5% (p=0.04). However, volume reduction was only partially attributed to serum testosterone levels ($R^2 = 0.28$) and the study does not report data on event free and overall survival. Three patients with tumor recurrence showed a reduction in JNA volume of 7%, 12% and 18%, suggesting flutamide may be a treatment option in post-excision residual or recurrent intracranial and extracranial JNA. These pilot studies suggest that a six week course of flutamide may have some activity in treating recurrent JNA, particularly in post-pubertal boys. Further investigation into adjuvant or salvage flutamide treatment is warranted, as the current evidence on flutamide efficacy is not entirely convincing.

Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β). Its expression is up-regulated in actively proliferating endothelial cells and it is selectively expressed on vascular tumor tissue (3). Wang et al retrospectively examined endoglin expression on JNA in...
seventy patients, with a median age of 17 years (5). Immunohistochemistry detected its expression on vascular endothelial cells (but not stromal cells) and revealed that the CD105-based microvessel density (MVD) correlated with JNA recurrence ($p=0.013$).

The vascular endothelial growth factor (VEGF) pathway plays a key role in solid tumor angiogenesis. Saylam et al found that 24 of 27 JNA samples were VEGF positive, including all cases of recurrence tested (17). Bevacizumab is a humanized monoclonal antibody that inhibits VEGF-A and could be a potential therapeutic option, although there are no reports of VEGF inhibitors being investigated as treatment for JNA to date.

Schick et al found that estrogen receptor alpha mRNA is more significant in JNA cell lines than in the stroma of nasal mucosa (18). The estrogen receptor antagonist tamoxifen was also demonstrated to inhibit proliferation of cultured JNA mesenchymal cells. However, side-effects of tamoxifen limit its clinical use for this indication. Selective estrogen antagonists are being developed, but other specific molecular targets currently remain a more realistic option for experimental treatment of JNA.

Wendler et al demonstrated the greater anti-proliferative effects of glucocorticoids on 30 JNA tissue samples compared to 20 nasal mucosa tissues in vitro (19). They also showed up-regulation of glucocorticoid receptors in JNA tissue compared to nasal mucosa. Glucocorticoids are reported to downregulate VEGF, reducing microvessel density and tumor volume (19). This is of particular interest in JNA because of previously described overexpression of VEGF (17), making glucocorticoids an intriguing but untested option for management of unresectable or recurrent JNA.
The mTOR (mammalian target of rapamycin) inhibitor sirolimus (rapamycin) and its analogues may offer effective targeted treatment for JNA, due to its highly vascular nature. They are potent inhibitors of serine/threonine kinase, which control cellular growth processes. Notably they appear to have antiangiogenic activity and have led to partial response in a case series of six patients with kaposiform hemangioendotheliomas (20).

Beta blockers are used in infantile hemangiomas to reduce the expression of VEGF and it has been theorized that propranolol induces apoptosis due to involvement of β1-adrenoreceptors in angiogenesis (20). Both mTOR inhibitors and beta blockers are options for further research into JNA treatment.

Conclusion

Managing recurrent and unresectable JNA remains a challenge. The absence of randomized control trials for anti-neoplastic drugs and RT means the role of adjuvant therapy is not well established. The greatest body of evidence surrounds radiation therapy or a six week course of flutamide, but both are based on small cohorts. Dexamethasone is a possible therapeutic option due to its potential impact on multiple pathways, but this is yet to be proven in a clinical setting. There is a biological rationale for anti-angiogenic agents and trials on anti-endoglin monoclonal antibodies are on-going, but VEGF-inhibitors such as bevacizumab have yet to be investigated. Should recurrence occur in the patient described in this case, the evidence-base for effective treatment is limited, particularly as being pre-pubertal reduces the potential benefit of flutamide. Radiotherapy is likely to remain the next most rational course of therapy. It has been demonstrated to effectively reduce tumor volume and is the best option for long term survival despite the potential side effects, until more targeted therapeutic options are fully evaluated. JNA is a biologically rich tumor and there is a clear need for
clinical research to evaluate adjuvant treatments to improve the outcome for recurrent and inoperable JNA.

Acknowledgements

The authors would like to thank Carl H. Snyderman C, Elizabeth C. Tyler-Kabara and Paul A. Gardner at the University Of Pittsburgh Medical Centre (UPMC) for their invaluable advice and surgical expertise in managing the case described.
References


**Figures**

**Figure 1:** Coronal MRI image showing an extensive JNA extending laterally into the pterygopalatine and masseter spaces and inferiorly into the infratemporal fossa. It extends into the right cavernous sinus and involves the right Meckel's cave.

**Figure 2:** Pathology micrographs of the JNA featured in the case: 2a) Hematoxylin and eosin stain; 2b) β-Catenin stain; 2c) Vimentin stain.